Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH 44106, USA.
Hum Mol Genet. 2021 Oct 1;30(R2):R264-R273. doi: 10.1093/hmg/ddab191.
The causative gene in cystic fibrosis (CF) was identified in 1989, 3 years before the publication of the first issue of Human Molecular Genetics. The cystic fibrosis transmembrane conductance regulator (CFTR) gene was among the first underlying a common inherited disorder to be cloned, and hence, its subsequent utilization toward a cure for CF provides a roadmap for other monogenic diseases. Over the past 30 years, the advances that built upon knowledge of the gene and the CFTR protein to develop effective therapeutics have been remarkable, and yet, the setbacks have also been challenging. Technological progress in other fields has often circumvented the barriers. This review focuses on key aspects of CF diagnostics and current approaches to develop new therapies for all CFTR mutations. It also highlights the major research advances that underpinned progress toward treatments and considers the remaining obstacles.
囊性纤维化(CF)的致病基因于 1989 年被确定,这比《人类分子遗传学》第一期的出版早了 3 年。囊性纤维化跨膜电导调节因子(CFTR)基因是首批被克隆的导致常见遗传性疾病的基因之一,因此,它在 CF 治疗方面的后续应用为其他单基因疾病提供了蓝图。在过去的 30 年中,基于对基因和 CFTR 蛋白的了解而开发有效治疗方法的进展是显著的,但挫折也是具有挑战性的。其他领域的技术进步常常绕过了这些障碍。这篇综述聚焦于 CF 诊断的关键方面以及当前针对所有 CFTR 突变开发新疗法的方法。它还强调了支持治疗进展的主要研究进展,并考虑了尚存的障碍。